Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective therapy for hematological malignancies and inherited diseases. However, acute graft-versus-host-disease (aGVHD) is a major life-threatening complication after allo-HCT and there are few therapeutic options for severe steroid-refractory aGVHD. Preliminary studies on cotransplantation of mesenchymal stem cells (MSCs) have shown an improvement in or resolution of severe aGVHD. However, the underlying mechanism this immunosuppressive effect has not been elucidated. Most of the data suggest that this immunosuppressive effect involves soluble factors such as IL-6 or TGF-β as well as cell-cell contact dependence. MSCs interact either directly with T cells or indirectly via other immune cells such as dendritic cells and NK cells. Here we review the immunomodulatory function of MSCs in allo-HCT and their potential usefulness in the treatment or prevention of severe acute GVHD.
Keywords: Mesenchymal stem cells (MSCs), acute graft-versus-host disease (aGVHD), allogeneic hematopoietic cell transplantation (Allo-HCT), steroid-refractory acute GVHD
Current Stem Cell Research & Therapy
Title: Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation
Volume: 4 Issue: 4
Author(s): Tomomi Toubai, Sophie Paczesny, Yusuke Shono, Junji Tanaka, Kathleen P. Lowler, Chelsea T. Malter, Masaharu Kasai and Masahiro Imamura
Affiliation:
Keywords: Mesenchymal stem cells (MSCs), acute graft-versus-host disease (aGVHD), allogeneic hematopoietic cell transplantation (Allo-HCT), steroid-refractory acute GVHD
Abstract: Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective therapy for hematological malignancies and inherited diseases. However, acute graft-versus-host-disease (aGVHD) is a major life-threatening complication after allo-HCT and there are few therapeutic options for severe steroid-refractory aGVHD. Preliminary studies on cotransplantation of mesenchymal stem cells (MSCs) have shown an improvement in or resolution of severe aGVHD. However, the underlying mechanism this immunosuppressive effect has not been elucidated. Most of the data suggest that this immunosuppressive effect involves soluble factors such as IL-6 or TGF-β as well as cell-cell contact dependence. MSCs interact either directly with T cells or indirectly via other immune cells such as dendritic cells and NK cells. Here we review the immunomodulatory function of MSCs in allo-HCT and their potential usefulness in the treatment or prevention of severe acute GVHD.
Export Options
About this article
Cite this article as:
Toubai Tomomi, Paczesny Sophie, Shono Yusuke, Tanaka Junji, Lowler P. Kathleen, Malter T. Chelsea, Kasai Masaharu and Imamura Masahiro, Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation, Current Stem Cell Research & Therapy 2009; 4 (4) . https://dx.doi.org/10.2174/157488809789649269
DOI https://dx.doi.org/10.2174/157488809789649269 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Experimental Animal Models of Myocardial Damage in Regenerative Medicine Studies Involving Adult Bone Marrow Derived Stem Cells: Ethical and Methodological Implications
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot Topic: Innovative Therapeutical Approaches for Hematological Malignancies Based on Molecular Targeted Therapies (Executive Editor: Giorgio Zauli) ]
Current Pharmaceutical Design NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Sphingosine-1-Phosphate in Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Promising Therapies in Sickle Cell Disease
Cardiovascular & Hematological Disorders-Drug Targets Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Proteomic Analysis of Aqueous Humor Proteins Associated with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy
Current Proteomics Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Properties of Thalidomide and its Analogues
Recent Patents on Inflammation & Allergy Drug Discovery Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3
Current Medicinal Chemistry